UMEA, Sweden, August 6 /PRNewswire/ -- Omnio Healer AB, a pioneer company developing novel therapies for wound healing and anti-infection, today announced that it has entered into a partnership agreement with Eden Biodesign. Under the agreement Eden Biodesign will provide process development and cGMP production services relating to Omnio Healer's lead recombinant protein candidate.
Based on a novel therapeutic concept for wound healing and anti-infection, Omnio Healer is developing drug candidates with potent pro-inflammatory functions. The agreement with Eden Biodesign relates to the expression of proteins using mammalian cell culture for use against several clinical indications, but primarily for studies relating to chronic eardrum wounds.
Omnio Healer selected Eden Biodesign as its preferred manufacturing partner after an extensive due diligence exercise that evaluated numerous contract manufacturing organizations in both Europe and the United States. Eden Biodesign will undertake the development of a robust manufacturing process for the product leading to cGMP production for supplying clinical studies. Omnio Healer has also assessed Eden Biodesign as a potential future commercial manufacturer of the product using Eden's MHRA-inspected state-of-the-art cGMP manufacturing facilities located in Liverpool, UK.
Mats Stromqvist, CEO of Omnio Healer AB, said, "Our protein product has shown very promising preclinical results in wound healing indications. We are now very keen to take the next step and gain access to GMP-material for use in clinical trials. At the same time, we have every confidence that Eden Biodesign will become a valuable partner in this regard, providing both cGMP process development and production."
Eden Biodesign's CEO, Dr. Crawford Brown, commented, "We are extremely happy to have been selected by Omnio Healer to support the development of this important product. Based on our extensive experience, industry expertise and first class facilities we hope to be able to add considerable value and flexibility to Omnio Healer's development program."
About Omnio Healer
Omnio Healer AB is a pioneer company developing novel drug candidates based on a series of conceptual breakthroughs in inflammation research. This new, pro-inflammatory approach opens up completely new therapeutic strategies for wound healing and anti-infection. The company's lead drug candidate, aimed primarily at otological indications, has achieved very promising preclinical results and will enter a clinical development program in late 2010.
Since its foundation in 2006 Omnio Healer has assembled a strong management and development team. This includes world-renowned scientists within the field, experienced product development professionals and active investors led by Karolinska Development AB, providing access to a highly qualified network of biotechnology development resources. The company is based in Umea, Sweden. Find out more at http://www.omniohealer.com.
About Eden Biodesign
Eden Biodesign is a globally-integrated biopharmaceutical company offering consultancy, biopharmaceutical design and cGMP manufacturing services to leading biotech and pharmaceutical clients around the world. With a reputation for successfully commercializing biopharmaceutical products and processes, the company offers expertise and guidance in multiple sectors. Eden's world-class facilities and knowledge in process development, manufacturing, regulatory and technology transfer support ensure that Eden Biodesign offers much more than a traditional CMO. Find out more at http://www.EdenBiodesign.com.
SOURCE Omnio Healer AB
CONTACT: For more information, contact: Omnio Healer AB, Mats Stromqvist,
PhD, Professor, CEO Omnio Healer AB, Tel. +46-70-631-0035,
firstname.lastname@example.org. Eden Biodesign, John D. Wagner, Propel Marketing
Group, Tel. +44-919-796-9984, Jdwagner@PropelMG.com,